Skip to main content
Premium Trial:

Request an Annual Quote

Leica Biosystems, Ultivue to Comarket Platforms for Biomarker Detection

NEW YORK (GenomeWeb) – Leica Biosystems and Ultivue have signed a partnership to comarket their respective products for rapid, automated, multiplexed biomarker detection.

Specifically, the companies will market Ultivue's UltiMapper assays together with Leica's Bond Rx research staining platform for research applications.

UltiMapper single-step multiplexing assays feature DNA barcode-tagged antibodies, and are pre-optimized for the Bond Rx, enabling a fully automated solution that can create 30 five-color, multiplexed immunohistochemistry slides in less than six hours while preserving tissue morphology and integrity, the companies said.

"With tissue sample sizes decreasing, and scientific advancements expanding the number of actionable biomarkers, multiplexing is an increasingly common technique used by researchers to explore complex biology," Colin White, Leica's global vice president of advanced staining, said in a statement. "We are very pleased to be able to offer investigators an automated version of Ultivue's UltiMapper multiplexing technology on the Bond Rx, thereby supporting research excellence through workflow efficiency and stain consistency."

Philippe Mourere, senior vice president of commercial operations at Ultivue, added that the combined solution will enable translational and clinical researchers to co-localize markers on single cells and functionally characterize cellular interactions within the tumor microenvironment.